biosimilars News

Conferences and exhibitions provide networking opportunities with leaders from all sectors of biotechnology and pharmaceuticals.

Seamlessly Integrated R&D, Production, Sales and Marketing Processes to Ensure Success in this High Growth Market

Patent Expiry of Several Key Blockbuster Drugs worth $ 150 billion between 2010 and 2017 Sets Stage for Entry of Generics Manufacturers

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report.

The biotech market in South Korea is forecasted to grow at a CAGR of around 35% during 2010-2013, says RNCOS in its latest research study.

A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.

Driven by a strong growth in the sales of temperature sensitive healthcare products, IMARC Group expects the global healthcare cold chain logistics market to grow robustly in the coming years.

With billions of dollars worth of biologic drugs going off patient in the next decade, this industry is set to expand at an intensive rate, and the importance of being fully informed of how you and your business will be affected is paramount.

The South Korean biotech industry is expected to grow at a CAGR of around 35% during 2010-2013, thereby contributing majorly to the Asia Pacific biotech market, says RNCOS in its latest research.

The Asia Pacific biotech market is expected to grow at a CAGR of around 19% during 2010-2013 on the back of demographic factors and increasing investments in the industry, says RNCOS.

Patent Expiries in Near Future Will Drive Generics’ Growth

With billions of dollars worth of biologic drugs going off patient in the next decade, this industry is set to expand at an intensive rate, and the importance of being fully informed of how you and your business will be affected is paramount.

Attend the one event where the industry leaders driving the business of biosimilars unite to set the standards which will shape an evolving legal and regulatory landscape

GPCR & Kinase Targets Advances in drug discovery from molecular to clinical 14th - 15th April 2011, Thistle City Barbican, London, UK

The report provides a comprehensive insight into the biosimilar market. It offers geography-wise as well as category-wise market forecasts for biosimilars and provides the drivers and restraints affecting the biosimilars market.

The report provides extensive information and rational analysis of the global monoclonal antibodies market.

New Pharmaceuticals research report from Business Insights is now available from Fast Market Research

In 2009 the Biotechnology Industry was Dominated by the Top 10 Companies

Aarkstore.com announce a new report "Global Biosimilars (Follow-on biologics) Market: An Analysis " through its vast collection of market research report.

Bharatbook added a new report on "Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025" which predicts how the biosimilars market will develop from 2010 onwards.

La Cátedra Curaxys se dedicará al desarrollo de medicamentos biológicos, y a la formación de investigadores y gestores especializados en biotecnología

Recently published report Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 will provide you with information that you need to understand current trends and future possibilities for those drugs.

U.S. legal situation holding market back

Fast Market Research recommends "The Global Active Pharmaceutical Ingredients (API) Market: Evaluating challenges, opportunities, innovations and the market environment" from Business Insights, now available

How have recent shifts in the health care reform debate changed the outlook of biosimilars legislation, and how could inappropriate legislation stifle the innovation inherent in the biotech industry? The experts weigh in.

The report provides insights on the biosimilars market revenues and growth until 2015. Further, the distribution of revenues across key geographies such as the US, the top five countries in Europe and Japan are provided in the report...

A multidisciplinary team of researches specialized on Biotechnology, Biomedicine, Science and Environmental sciences, will research in new processes for the biosimilars production.

Un equipo multidisciplinar de la Universidad, de Biotecnología, Ciencias y Medio Ambiente, investigará en productos biogenéricos

The biosimilars production has been incorporate to the new technological platforms of Curaxys in order to get more competitive processes and products. Curaxys has been pioneer in the use of those technologies, mainly in the baculovirus expression sys

Curaxys is the new company specialized in the production of biosimilars medicines. It is an independent private company, located on the technological park of Cadiz (Spain). The new venture is focuses in the development of new technological platform f

Bharatbook.com added a new report on "Europe Active Pharmaceuticals Ingredients Market Analysis and Forecasts to 2020" focus the Growth Of The Innovative Sector Of The Synthetic API Market In Europe.

Bharatbook.com included " Biosimilars and Biobetters: Positioning for a New Market " that provides information on biosimilars and production of therapeutic peptides and proteins

Monoclonal antibodies in cancer therapy – significant commercial opportunities with developing technologies and innovative products – our new report explains prospects

There is great demand for lower-cost biological drugs: commercial and regulatory developments will make biosimilars and follow-on biologics a success – our new report explains how- Revenues for biologic drugs reached approximately $125bn in 2008.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report which provides an up-to-date overview of the latest changes within the global generic market over the last 18 months.

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which says Europe is far ahead of the U.S when it comes to approving the use of biosimilars.